期刊文献+

HPLC测定维格列汀中的2种基因毒性杂质 被引量:1

Determination of Two Genotoxic Impurities in Vildagliptin by HPLC
下载PDF
导出
摘要 目的:采用HPLC法测定维格列汀中的两种潜在基因毒性杂质。方法:采用KromasilC18色谱柱(250 mm×4.6 mm,5μm),流动相A为0.21%辛烷磺酸钠溶液(磷酸调节pH值至2.1),流动相B为乙腈,梯度洗脱,流速1.0 mL·min^-1,检测波长210 nm,柱温30℃。结果:维格列汀峰与两个基因毒性杂质峰的分离度均大于3.0,两个基因毒性杂质的线性范围均为0.015~0.9μg·mL^-1(r>0.998),检测限分别为0.091 ng、0.095 ng,平均回收率分别为99.0%、93.2%,RSDA=4.7%、RSDB=5.4%。结论:所用方法专属性强、准确性好、灵敏度高、操作简便,适用于维格列汀基因毒性杂质的测定。 To determine the potential genotoxic impurities in vildagliptin by HPLC.A Kromasil C18 column(250 mm×4.6 mm,5μm) was used in HPLC system;The mobile phase A was 0.21% octane sulfonic acid sodium salt solution(regulated by phosphoric acid to pH of 2.1) and the mobile phase B was acetonitrile in gradient elution at a flow rate of 1.0 mL·min^-1 with 210 nm detection wavelength.The temperature of the column was maintained at 30℃.The Injection volume was 20 μL.The two genotoxic impurities could be well separated from vildagliptin,The linear range of the two genotoxic impurities exhibited a good linear relationship from0.015~0.9 μg·mL^-1(r>0.998),The LOD were 0.091 ng and 0.095 ng.The average recoveries for impurity A and impurity B were 99.0% and 93.2% with RSD of 4.7% and 5.4% respectively.The method is simple,specific,accurate and sensitive. It is applicable to be used for the determination of the potential genotoxic impurities in vildagliptin.
作者 吴文惠 王少卿 Wu Wenhui;Wang Shaoqing(Department of pharmacy,Shandong University of Traditional ChineseMedicine,Jinan 250355,China;Yantai Valiant Pharmaceutical Co.,Ltd.,Yantai 264006,China)
出处 《山东化工》 CAS 2019年第15期107-110,共4页 Shandong Chemical Industry
关键词 维格列汀 基因毒性杂质 高效液相色谱法 梯度洗脱 毒理学关注阈值 vildagliptin genotoxic impurity HPLC gradient elution TTC
  • 相关文献

参考文献4

二级参考文献25

  • 1N.V.V.S.S.Raman,A.V.S.S.Prasad,K.Ratnakar Reddy,K.Ramakrishna.Determination of genotoxic alkyl methane sulfonates and alkyl paratoluene sulfonates in lamivudine using hyphenated techniques[J].Journal of Pharmaceutical Analysis,2012,2(4):314-318. 被引量:9
  • 2王彦.盐酸阿扎司琼有机溶剂残留量测定[J].药物分析杂志,2004,24(3):293-295. 被引量:3
  • 3Pratley RE, Salsali A, Matfin G. Inhibition of dispeptidyl peptidase-4 with vildagliptin:a potential new treatment for type 2 diabetes [J]. Br J Diabetes Vasc Dis, 2006,6(4): 150-156.
  • 4Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3- Hydroxy- 1-adamantyl) amino I acetyl ]-2-cyano-( S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase Ⅳ inhibitor with antihyperglycemic properties [J]. J Med Chem, 2003,46(13) : 2774-2789.
  • 5Pi-Sunyer FX, Schweizer A, Mills D, et ol. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type Ⅱ diabetes [J]. Diabetes Res Clin Practice, 2007,76(1): 132-138.
  • 6Bosi E, Camisasca RP, Collober C, et al. Effects of vildag- liptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [J]. Diabetes Care, 2007; 30(4): 890-895.
  • 7威尔豪尔EB.N-取代2-氰基吡咯烷类化合物:CN,1160330C[P].2004-08-04.
  • 8Schafer F, Adelhausen R, Schallstadt GS. Process for the pre- paration of N-substituted 2-cyanopyrrolidines: US, 2006/ 0199854A1 [P]. 2008-09-07.
  • 9Ales H, Bozena K, Tomas C. A method of preparation of highly pure vildagliption: WO, 2010/022690A2 [P]. 2010-03-04.
  • 10Marco B. Process and intermediates for preparation of an active ingredient: WO, 2012004210A1 [P]. 2012-01-12.

共引文献67

同被引文献16

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部